Skip to main content

Table 1 Demographics and other baseline characteristics

From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

 

Statistic

Placebo

(N = 60)

PQ912

(N = 60)

Age (years)

Mean (SD)

72 (7)

70.8 (8)

Sex

 Female

n (%)

28 (47)

36 (60)

 Male

n (%)

32 (53)

24 (40)

MMSE

Mean (SD)

24.8 (3)

25.2 (3)

APoE

 E4

n (%)

43 (72)

38 (63)

  1. APoE apolipoprotein E, MMSE Mini Mental State Examination, N number of subjects in population, n number of subjects, SD standard deviation
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193